Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Above 50-Day Moving Average - What's Next?

Key Points

• Genmab A/S shares have crossed above their 50-day moving average of $238.88, trading at a high of $272.30.
• The company reported an EPS of $5.42 for the last quarter, surpassing analysts' expectations of $3.99.
• Genmab A/S has a market cap of $17.99 billion and a PE ratio of 13.67, indicating solid performance metrics.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $238.88 and traded as high as $272.30. Genmab A/S shares last traded at $272.30, with a volume of 24 shares trading hands.

Genmab A/S Price Performance

The firm's 50 day moving average price is $241.62 and its 200-day moving average price is $216.28. The firm has a market cap of $18.63 billion, a price-to-earnings ratio of 14.16 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $5.42 EPS for the quarter, beating the consensus estimate of $3.99 by $1.43. The firm had revenue of $925.00 million during the quarter, compared to analysts' expectations of $949.06 million. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.